tarafenacin
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2006 (NCT00507169)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Muscarinic acetylcholine receptor M3ANTAGONIST
CHRM3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O[C@H]1CN2CCC1CC2)N(Cc1cc(F)c(F)c(F)c1)c1cccc(F)c1- Mol. weight
- 408.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1779046 ↗
Also known as
- svt-40776
- svt-40776
- svt-40776
- tarafenacin
- tarafenacin
- tarafenacin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01458197 | Phase 2 | Sep 1, 2011 | Kwang Dong Pharmaceutical co., ltd., University of Ulsan |
| NCT00507169 | Phase 2 | Sep 1, 2006 | Salvat |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kwang Dong Pharmaceutical co., ltd. | For profit | 1 | 1 | 1 | 2011 |
| Salvat | For profit | 1 | 1 | 1 | 2006 |
| University of Ulsan | Academic/Hospital | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1